Annual report pursuant to Section 13 and 15(d)

Consolidated Statement of Shareholders' Equity (Deficit)

v3.22.1
Consolidated Statement of Shareholders' Equity (Deficit) - USD ($)
$ in Thousands
Total
Cumulative Effect Period Of Adoption Adjustment [Member]
Cumulative Effect Period Of Adoption Adjusted Balance [Member]
Series P2 Convertible Preferred Stock [Member]
Previously Reported [Member]
Preferred Stock [Member]
Convertible Preferred Stock [Member]
Cumulative Effect Period Of Adoption Adjustment [Member]
Preferred Stock [Member]
Previously Reported [Member]
Convertible Preferred Stock [Member]
Common Stock [Member]
Common Stock [Member]
Cumulative Effect Period Of Adoption Adjustment [Member]
Common Stock [Member]
Cumulative Effect Period Of Adoption Adjusted Balance [Member]
Common Stock [Member]
Series P2 Convertible Preferred Stock [Member]
Common Stock [Member]
Previously Reported [Member]
Additional Paid in Capital [Member]
Additional Paid in Capital [Member]
Cumulative Effect Period Of Adoption Adjustment [Member]
Additional Paid in Capital [Member]
Cumulative Effect Period Of Adoption Adjusted Balance [Member]
Additional Paid in Capital [Member]
Series P2 Convertible Preferred Stock [Member]
Additional Paid in Capital [Member]
Previously Reported [Member]
Accumulated Deficit [Member]
Accumulated Deficit [Member]
Cumulative Effect Period Of Adoption Adjusted Balance [Member]
Accumulated Deficit [Member]
Previously Reported [Member]
Beginning balance at Dec. 31, 2019   $ 129,921 $ 2,978   $ (126,943) $ (129,921) $ 129,921   $ (53) $ 6   $ 59   $ 129,974 $ 170,600   $ 40,626   $ (167,628) $ (167,628)
Beginning balance, Shares at Dec. 31, 2019           (153,758,348) 153,758,348   (1,992,064) 63,204,426   65,196,490                
Issuance of common stock upon exercise of stock options $ 66             $ 1         $ 65              
Issuance of common stock upon exercise of stock options, Shares 5,318,139             5,318,139                        
Vesting of early exercised stock options $ 21                       21              
Issuance of series P-2 Preferred stock Number of shares issued                     27,989,240                  
Issuance of Series P-2 convertible preferred stock       $ 63,932             $ 3         $ 63,929        
Repurchase of unvested restricted common stock, Shares               (3,230)                        
Conversion of promissory notes to Series P-2 convertible preferred stock       $ 8,203                       $ 8,203        
Conversion of promissory notes to Series P-2 convertible preferred stock, Shares                     3,507,984                  
Stock-based compensation 666                       666              
Net loss (39,650)                                 $ (39,650)    
Ending balance at Dec. 31, 2020 $ 36,216             $ 10         243,484         (207,278)    
Ending balance, Shares at Dec. 31, 2020 100,016,559             100,016,559                        
Issuance of common stock upon exercise of stock options $ 62                       62              
Issuance of common stock upon exercise of stock options, Shares 2,180,168             2,180,168                        
Vesting of early exercised stock options $ 111                       111              
Repurchase of unvested restricted common stock, Shares               (433,359)                        
Issuance of Series D convertible preferred stock upon exercise of warrants 20,877                       20,877              
Issuance of Series D convertible preferred stock upon exercise of warrants, Shares               2,020,034                        
Business combination, net of redemptions and equity issuance costs and PIPE financing, net 300,745             $ 4         300,741              
Business combination, net of redemptions and equity issuance costs and PIPE financing, net, Shares               41,249,985                        
Issuance of common stock upon exercise of common stock warrants, value 82,546             $ 1         82,545              
Issuance of common stock upon exercise of common stock warrants, shares               7,177,885                        
Vesting of restricted stock units               61,015                        
Stock-based compensation 11,434                       11,434              
Net loss (125,874)                                 (125,874)    
Ending balance at Jan. 02, 2022 $ 326,117             $ 15         $ 659,254         $ (333,152)    
Ending balance, Shares at Jan. 02, 2022 152,272,287             152,272,287